William Blair analyst Brandon Vazquez has maintained their bullish stance on ABT stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that suggest a promising future for Abbott Laboratories. Despite some short-term challenges, such as a slight miss in third-quarter growth expectations and lower gross margins, the company’s medical device segment showed strong growth. This segment’s performance, alongside effective control of operating expenses, helped maintain earnings per share in line with expectations.
Looking ahead, Vazquez highlights several growth drivers that position Abbott Laboratories favorably for the future. These include overcoming significant headwinds in diagnostics, securing key contracts in nutrition, and making progress with regulatory filings expected to launch in 2026. Additionally, the company is poised to benefit from the expansion of key medical device products, such as Volt, Libre, and Navitor, which are expected to contribute to double-digit EPS growth by 2026. These factors underpin Vazquez’s confidence in the stock’s potential, justifying the Buy rating.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $153.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.